Scientists Fix Immune Disease Gene in Patient Stem Cells

Scientists have just taken a major step toward curing genetic immune diseases at their source rather than just treating symptoms.

Researchers at Aarhus University in Denmark successfully repaired a genetic defect in blood stem cells taken from a patient with GATA2 deficiency. People born with this condition don't produce enough immune cells, leaving them vulnerable to constant infections and serious illness.

The team used a new technique called prime editing to fix the broken gene. Postdoctoral researcher Jonas Holst Wolff and Professor Jacob Giehm Mikkelsen published their findings in Science Translational Medicine, showing that the method corrected part of the genetic defect in patient stem cells.

Prime editing works differently than traditional CRISPR gene editing. Instead of cutting all the way through DNA, which can cause unintended changes elsewhere in the genetic code, prime editing gently inserts correct DNA at the exact spot where the defect exists. This makes it more precise and safer for delicate stem cells.

The results exceeded basic expectations. Patients with GATA2 deficiency start with about half their gene copies functioning normally. After editing, that proportion jumped from 50% to 70%, and the researchers saw real improvements in how the affected protein worked.

"This shows that we do not necessarily need to correct every gene copy," Wolff explains. "What matters is whether we can improve the cells' function enough to make a difference for the patient."

The Ripple Effect

The technique isn't just about one rare disease. Wolff believes prime editing could work for many inherited conditions as long as researchers know the precise genetic defect causing them.

Right now, some GATA2 patients can receive donor stem cells, but the treatment doesn't work for everyone. Prime editing could become a lifeline for patients with no other options, using their own corrected cells instead of waiting for compatible donors.

The research team's next challenge is scaling up the process to edit the much larger number of stem cells needed for actual patient treatment. They also need to identify which patients with immune deficiencies would benefit most from this approach.

"Our goal is to develop a treatment tailored to the specific genetic defect in each individual patient," Wolff says. If they succeed, it could open new possibilities for people living with rare inherited diseases who have been waiting their whole lives for real solutions.